BACKGROUND: There have been several studies assessing the epidemiology and effects of tobacco smoke in the cystic fibrosis (CF) population, but few address the efforts of smoking cessation interventions. Our objective is to present one tobacco prevention and cessation programme targeting patients with CF in the Mediterranean region of Murcia (Spain). METHODS: All registered patients in the Regional CF unit (n=105) in 2008 were included in a cross-sectional and prospective uncontrolled study of tobacco use and exposure in CF patients using a baseline and 1-year follow-up. Target population includes both patients and other family members living at home. The study included an initial telephone questionnaire, measurement of lung function, urinary cotinine levels, and several telephone counselling calls and/or personalised smoking cessation services. RESULTS: Of the 97 contacted patients, 59.8% (n=58) were exposed to environmental tobacco smoke (ETS), 12.4% (n=12) had smoked at one time, and 14.3% (n=8) of patients over the age of 15 actively smoked. The mean age was 31.13 (range: 19-45). Of the non-smokers (n=89), 56.2% reported ETS and 26.9% live with at least one smoker at home. 49.2% had urinary cotinine levels >10 ng/ml. The correlation found between patients' cotinine levels and their reported tobacco exposure was (0.77, p<0.0001). Active smoking by mothers during pregnancy was associated with significantly lower lung function in young CF patients (-0.385, p=0.04). At the 1-year follow-up, 13 individuals made attempts to stop smoking, 6 of which are now ex-smokers (12.5% of all smokers). CONCLUSIONS: Smoking during pregnancy adversely affects lung function in individuals with CF. Tobacco prevention and cessation programmes are an effective and vital component for CF disease management. The trained professionals in prevention and smoking cessation services could provide patients with adequate follow-up, integrating an environmental health approach into CF patients' healthcare.
BACKGROUND: There have been several studies assessing the epidemiology and effects of tobacco smoke in the cystic fibrosis (CF) population, but few address the efforts of smoking cessation interventions. Our objective is to present one tobacco prevention and cessation programme targeting patients with CF in the Mediterranean region of Murcia (Spain). METHODS: All registered patients in the Regional CF unit (n=105) in 2008 were included in a cross-sectional and prospective uncontrolled study of tobacco use and exposure in CF patients using a baseline and 1-year follow-up. Target population includes both patients and other family members living at home. The study included an initial telephone questionnaire, measurement of lung function, urinary cotinine levels, and several telephone counselling calls and/or personalised smoking cessation services. RESULTS: Of the 97 contacted patients, 59.8% (n=58) were exposed to environmental tobacco smoke (ETS), 12.4% (n=12) had smoked at one time, and 14.3% (n=8) of patients over the age of 15 actively smoked. The mean age was 31.13 (range: 19-45). Of the non-smokers (n=89), 56.2% reported ETS and 26.9% live with at least one smoker at home. 49.2% had urinary cotinine levels >10 ng/ml. The correlation found between patients' cotinine levels and their reported tobacco exposure was (0.77, p<0.0001). Active smoking by mothers during pregnancy was associated with significantly lower lung function in young CF patients (-0.385, p=0.04). At the 1-year follow-up, 13 individuals made attempts to stop smoking, 6 of which are now ex-smokers (12.5% of all smokers). CONCLUSIONS: Smoking during pregnancy adversely affects lung function in individuals with CF. Tobacco prevention and cessation programmes are an effective and vital component for CF disease management. The trained professionals in prevention and smoking cessation services could provide patients with adequate follow-up, integrating an environmental health approach into CF patients' healthcare.
Authors: Juan Antonio Ortega García; Josep Ferrís i Tortajada; Juan Alonso López Andreu Journal: Int J Hyg Environ Health Date: 2007-08-30 Impact factor: 5.840
Authors: M T Britto; J M Garrett; M A Dugliss; C W Daeschner; C A Johnson; M W Leigh; J M Majure; W H Schultz; T R Konrad Journal: Pediatrics Date: 1998-02 Impact factor: 7.124
Authors: Juan Antonio Ortega-García; Joseph E Perales; Alberto Cárceles-Álvarez; Miguel Felipe Sánchez-Sauco; Seiichi Villalona; Pedro Mondejar-López; María Dolores Pastor-Vivero; Pilar Mira Escolano; Diana Carolina James-Vega; Manuel Sánchez-Solís Journal: Adicciones Date: 2016-03-02 Impact factor: 2.979
Authors: Gabriela R Oates; William T Harris; Hector H Gutierrez; Cathy Mims; Sarah B Rutland; Corilyn Ott; Soumya J Niranjan; Isabel C Scarinci; Susan C Walley Journal: Pediatr Pulmonol Date: 2020-06-08
Authors: Gabriela R Oates; Elizabeth Baker; Joseph M Collaco; Steven M Rowe; Sarah B Rutland; Christopher M Fowler; William T Harris Journal: J Cyst Fibros Date: 2021-07-17 Impact factor: 5.527
Authors: Benjamin T Kopp; Juan Antonio Ortega-García; S Christy Sadreameli; Jack Wellmerling; Estelle Cormet-Boyaka; Rohan Thompson; Sharon McGrath-Morrow; Judith A Groner Journal: Int J Environ Res Public Health Date: 2016-10-12 Impact factor: 3.390